Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT
Manage episode 288868984 series 2602288
Player FM과 저희 커뮤니티의 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completion of this activity, participants should be better able to: Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML, Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting.